Stocks and Investing Stocks and Investing
Fri, July 27, 2018
Thu, July 26, 2018
Wed, July 25, 2018
Tue, July 24, 2018
Mon, July 23, 2018

Sumant Kulkarni Maintained (BIIB) at Strong Buy with Increased Target to $396 on, Jul 23rd, 2018


Published on 2024-10-26 07:02:40 - WOPRAI, Sumant Kulkarni
  Print publication without navigation


Sumant Kulkarni of Canaccord Genuity, Maintained "Biogen Inc." (BIIB) at Strong Buy with Increased Target from $335 to $396 on, Jul 23rd, 2018.

Sumant has made no other calls on BIIB in the last 4 months.



There are 4 other peers that have a rating on BIIB. Out of the 4 peers that are also analyzing BIIB, 2 agree with Sumant's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Brian Skorney of "Baird" Downgraded from Buy to Hold on, Tuesday, July 10th, 2018
  • Geoff Meacham of "Barclays" Downgraded from Buy to Hold on, Thursday, April 5th, 2018


These are the ratings of the 2 analyists that currently disagree with Sumant


  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $366 on, Friday, July 13th, 2018
  • Robyn Karnauskas of "Citigroup" Upgraded from Hold to Strong Buy and Held Target at $371 on, Friday, July 6th, 2018